October 2009 Volume 6 Number 10
Visit Nature Reviews Clinical Oncology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=26&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Clinical Oncology online. To purchase a subscription,
please visit:
http://links.ealert.nature.com/ctt?kn=71&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=52&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
*********************************************************************
Nature Reviews Clinical Oncology Impact Factor: 9.113*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
AACR Conference:
Advances in Breast Cancer Research: Genetics, Biology and Clinical
Applications
October 13-16, 2009 - San Diego, CA
Carlos L. Arteaga, Lewis A. Chodosh, and Kornelia Polyak, Chairpersons
Presenting discoveries in genetics, cell biology, and molecular biology
relevant to breast cancer development and progression. Please visit:
http://links.ealert.nature.com/ctt?kn=39&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
Focus on p53 - 30 years on
To celebrate the past 30 years of research on p53, Nature Reviews Cancer
presents a Focus issue of specially-commissioned articles that discuss
the many roles of this tumor suppressor.
To access the Focus:
http://links.ealert.nature.com/ctt?kn=78&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
A p53 molecular network map is now available from the NCI-Nature Pathway
Interaction Database, and depicts both the mechanisms by which this
transcription factor is stabilized and activated as well as numerous
p53 downstream effectors.
View the FREE network map online:
http://links.ealert.nature.com/ctt?kn=59&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
The Holy Grail of biomarkers
Lisa Hutchinson and Vincent T. DeVita Jr
p553 | doi:10.1038/nrclinonc.2009.145
http://links.ealert.nature.com/ctt?kn=21&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Immunotherapy: HPV-16/18 vaccine is highly effective against cervical
infection
p555 | doi:10.1038/nrclinonc.2009.134
http://links.ealert.nature.com/ctt?kn=24&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Medical oncology: Vascular normalization predicts response to cediranib
p556 | doi:10.1038/nrclinonc.2009.137
http://links.ealert.nature.com/ctt?kn=8&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Overdiagnosis with mammography?
p556 | doi:10.1038/nrclinonc.2009.138
http://links.ealert.nature.com/ctt?kn=10&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Chemotherapy: Metastatic breast cancer-optimal front-line therapy
p557 | doi:10.1038/nrclinonc.2009.135
http://links.ealert.nature.com/ctt?kn=13&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Surgery: Rectal cancer-treatment on the less invasive side
p557 | doi:10.1038/nrclinonc.2009.136
http://links.ealert.nature.com/ctt?kn=95&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
ER-[alpha]36 and resistance to tamoxifen
p558 | doi:10.1038/nrclinonc.2009.132
http://links.ealert.nature.com/ctt?kn=98&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Medical oncology: PSA is best outcome predictor
p558 | doi:10.1038/nrclinonc.2009.133
http://links.ealert.nature.com/ctt?kn=88&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Chemotherapy: Topotecan or treosulfan-that is the question
Maurie Markman
p559 | doi:10.1038/nrclinonc.2009.144
Meier and coauthors found that topotecan improved progression-free and
overall survival compared with treosulfan in patients with recurrent
ovarian cancer following platinum and taxane-based therapy. Although
these results are promising, the optimum treatment strategy for patients
with recurrent ovarian cancer still remains to be determined.
http://links.ealert.nature.com/ctt?kn=91&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Chemotherapy: Optimizing irinotecan regimens for colorectal cancer
Kein-Leong Yim and David Cunningham
p560 | doi:10.1038/nrclinonc.2009.140
Second-line irinotecan regimens are efficacious in patients with advanced
colorectal cancer who experience disease progression on first-line
oxaliplatin-based chemotherapy. Bidard et al. investigated the impact
of treatment with dose-dense irinotecan on improving survival in such
patients and aimed to optimize the irinotecan combination chemotherapy
platform.
http://links.ealert.nature.com/ctt?kn=92&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?
Faye M. Johnson and Bonnie S. Glisson
p562 | doi:10.1038/nrclinonc.2009.141
The results of a large, randomized, North American trial (SWOG S0124)
that compared etoposide and cisplatin with irinotecan and cisplatin
for patients with extensive small-cell lung cancer have failed to
confirm the benefit observed with irinotecan that was demonstrated
in an earlier Japan Clinical Oncology Group study (JCOG 9511).
http://links.ealert.nature.com/ctt?kn=7&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Chemotherapy: Adjuvant chemotherapy in older patients with breast cancer
Agnes Jager, Jaap Verweij and Stefan Sleijfer
p563 | doi:10.1038/nrclinonc.2009.142
A prospective, randomized trial has shown that standard adjuvant
chemotherapy is superior to capecitabine in the treatment of women with
breast cancer aged 65 years or older; on the basis of the results of
this study, capecitabine cannot be recommended in this setting.
http://links.ealert.nature.com/ctt?kn=3&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Hematology: Thalidomide maintenance in multiple myeloma
Jacob P. Laubach, Paul G. Richardson and Kenneth C. Anderson
p565 | doi:10.1038/nrclinonc.2009.131
Thalidomide is frequently used in patients with newly diagnosed and
relapsed multiple myeloma, but its role as maintenance therapy following
autologous stem-cell transplantation has been an area of uncertainty.
In this article we consider the efficacy of thalidomide maintenance
therapy in multiple myeloma.
http://links.ealert.nature.com/ctt?kn=5&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Radiotherapy: IMRT reduces xerostomia and potentially improves QoL
Avraham Eisbruch
p567 | doi:10.1038/nrclinonc.2009.143
Xerostomia and reduced quality of life are common occurrences in patients
treated with radiation to the salivary gland for head and neck
squamous-cell carcinoma. This article discusses outcomes after
intensity-modulated radiation therapy and three-dimensional conventional
radiotherapy among patients with head and neck squamous-cell carcinoma.
http://links.ealert.nature.com/ctt?kn=16&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Article series: Antiangiogenic Clinical Strategies
An overview of small-molecule inhibitors of VEGFR signaling
S. Percy Ivy, Jeannette Y. Wick and Bennett M. Kaufman
Published online: 08 September 2009
p569 | doi:10.1038/nrclinonc.2009.130
The VEGFR small-molecule inhibitors of angiogenesis show promise for
oncology patients. These rationally designed inhibitors are being tailored
for use in specific malignancies and will have a pivotal role in
personalized medicine. The authors discuss the potential of these agents
for treating tumors such as metastatic renal-cell carcinoma, GIST and
hepatocellular carcinoma.
Abstract: http://links.ealert.nature.com/ctt?kn=67&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=33&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Role of cancer stem cells in pancreatic ductal adenocarcinoma
Gregory Sergeant, Hugo Vankelecom, Lies Gremeaux and Baki Topal
Published online: 18 August 2009
p580 | doi:10.1038/nrclinonc.2009.127
With greater understanding of the biology of pancreatic cancer a role
for cancer stem cells is becoming clear. The authors of this Review
discuss the current knowledge on pancreatic cancer stem cells and their
potential use as targets in therapeutic regimens.
Abstract: http://links.ealert.nature.com/ctt?kn=48&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=30&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Src kinases as therapeutic targets for cancer
Lori C. Kim, Lanxi Song and Eric B. Haura
p587 | doi:10.1038/nrclinonc.2009.129
Src family kinases have been extensively studied and found to be central
mediators in multiple signaling pathways that are important in oncogenesis.
Preclinical studies have shown that SFK inhibitors can suppress tumor
growth and metastases. The authors of this Review discuss the potential
use of these agents to target cancer in humans.
Abstract: http://links.ealert.nature.com/ctt?kn=49&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=35&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Neurological adverse effects caused by cytotoxic and targeted therapies
David Schiff, Patrick Y. Wen and Martin J. van den Bent
Published online: 25 August 2009
p596 | doi:10.1038/nrclinonc.2009.128
With the development of new chemotherapy and targeted agents, neurotoxicity
has become increasingly important as a cause of dose-limiting toxicity.
The authors review the important and unusual neurotoxicities related to
chemotherapy and targeted agents approved since January 1999.
Abstract: http://links.ealert.nature.com/ctt?kn=53&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=40&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
Breast cancer in a BRCA2 mutation carrier with a history of prostate
cancer
Seema Panchal, Orli Shachar, Frances O'Malley, Pavel Crystal, Jaime
Escallon, Juanita Crook, Anita Bane and Louise Bordeleau
p604 | doi:10.1038/nrclinonc.2009.116
This case study discusses a patient initially diagnosed with high-risk
prostate cancer who underwent androgen deprivation therapy. The patient
subsequently presented with ductal carcinoma in situ and was found to
be a BRCA2 mutation carrier with a strong family history of breast cancer.
Abstract: http://links.ealert.nature.com/ctt?kn=55&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=43&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
Molecular imaging of solid tumors: exploiting the potential
Wim J. G. Oyen and Winette T. A. van der Graaf
p609 | doi:10.1038/nrclinonc.2009.139
Novel targeted therapies often result in disease stabilization rather
than tumor shrinkage, which are reflected by changes in the molecular
features of the tumor. Noninvasive procedures to measure such features
are urgently needed. The authors of this opinion article discuss the
role of PET and its impact on decisions about monitoring of systemic
cytotoxic and targeted therapy.
Abstract: http://links.ealert.nature.com/ctt?kn=56&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=46&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Visit the Nature Reviews Clinical Oncology website:
- Advanced online publication
- Search across related content from nature.com
- Web feeds (RSS)
- Downloadable PowerPoint slides of figures and supplementary information
- Links to the European School of Oncology, including e-grandrounds
http://links.ealert.nature.com/ctt?kn=79&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=51&m=34082529&r=MTc2NDg2OTc4MQS2&b=2&j=NTg2MjQ2MTIS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
